Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer

References

• Tariq N-U-A, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623–2642. doi:10.2147/CMAR.S157092
   PubMed Web of Science ®Google Scholar
• Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(S1):123–142. doi:10.1111/liv.14100
   PubMedGoogle Scholar
• Abril-Rodriguez G, Ribas A. SnapShot: immune Checkpoint Inhibitors. Cancer Cell. 2017;31(6):848–e1. doi:10.1016/j.ccell.2017.05.010
   PubMed Web of Science ®Google Scholar
• Miura T, Yoshizawa T, Hirai H, et al. Prognostic impact of CD163+ macrophages in tumor stroma and CD8+ T-cells in cancer cell nests in invasive extrahepatic bile duct cancer. Anticancer Res. 2017;37(1):183–190. doi:10.21873/anticanres.11304
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi:10.1038/ng.3375
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Mancham S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71(4):753–762. doi:10.1016/j.jhep.2019.05.026
   PubMed Web of Science ®Google Scholar
• Kim MH, Jang M, Kim H, Lee WJ, Kang CM, Choi HJ. Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of vater. Cancer Immunol Immunother. 2019;68(3):443–454. doi:10.1007/s00262-018-02293-6
   PubMed Web of Science ®Google Scholar
• Kriegsmann M, Roessler S, Kriegsmann K, et al. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. BMC Cancer. 2019;19(1):72. doi:10.1186/s12885-018-5254-0
   PubMed Web of Science ®Google Scholar
• Ueno T, Tsuchikawa T, Hatanaka KC, et al. Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. Oncotarget. 2018;9(28):20034–20047. doi:10.18632/oncotarget.25050
   PubMedGoogle Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(15):24644–24651. doi:10.18632/oncotarget.15602
   PubMedGoogle Scholar
• Ha H, Nam AR, Bang JH, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7(47):76604–76612. doi:10.18632/oncotarget.12810
   PubMedGoogle Scholar
• Ahn S, Lee Y, Kim JW, et al. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies. Histopathology. 2019;75(4):526–536. doi:10.1111/his.13901
   PubMed Web of Science ®Google Scholar
• Sangkhamanon S, Jongpairat P, Sookprasert A, et al. Programmed death-ligand 1 (PD-L1) expression associated with a high neutrophil/lymphocyte ratio in cholangiocarcinoma. Asian Pac J Cancer Prev. 2017;18(6):1671–1674. doi:10.22034/APJCP.2017.18.6.1671
   PubMedGoogle Scholar
• Yu F, Gong L, Mo Z, et al. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: possible immunotherapy implications. Biosci Trends. 2019;13(1):58–69. doi:10.5582/bst.2019.01003
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):470–478. doi:10.1158/1078-0432.CCR-15-0715
   PubMed Web of Science ®Google Scholar
• Loilome W, Kadsanit S, Muisook K, et al. Imbalanced adaptive responses associated with microsatellite instability in cholangiocarcinoma. Oncol Lett. 2017;13(2):639–646. doi:10.3892/ol.2016.5477
   PubMed Web of Science ®Google Scholar
• Goeppert B, Roessler S, Renner M, et al. Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol. 2019;14(1):36. doi:10.1186/s13000-019-0813-5
   PubMedGoogle Scholar
• Goeppert B, Roessler S, Renner M, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer. 2019;120(1):109–114. doi:10.1038/s41416-018-0199-2
   PubMed Web of Science ®Google Scholar
• Winkelmann R, Schneider M, Hartmann S, et al. Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German Tertiary Care Hospital. Int J Mol Sci. 2018;19(5):1421. doi:10.3390/ijms19051421
   PubMed Web of Science ®Google Scholar
• Czink E, Kloor M, Goeppert B, et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Cold Spring Harb Mol Case Stud. 2017;3(5):a001974. doi:10.1101/mcs.a001974
   PubMedGoogle Scholar
• Parks AL, McWhirter RM, Evason K, Kelley RK. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer. 2015;46(2):161–165. doi:10.1007/s12029-015-9690-7
   PubMedGoogle Scholar
• Bang Y-J, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol. 2019;37(15_suppl):4079. doi:10.1200/JCO.2019.37.15_suppl.4079
   Web of Science ®Google Scholar
• Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18(12):1169–1175. doi:10.1080/14737140.2018.1535315
   PubMed Web of Science ®Google Scholar
• Kim RD, Kim DW, Alese OB, et al. A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). J Clin Oncol. 2019;37(15_suppl):4097. doi:10.1200/JCO.2019.37.15_suppl.4097
   Google Scholar
• Fujiwara Y, Iguchi H, Yamamoto N, et al. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. Cancer Sci. 2019;110(5):1715–1723. doi:10.1111/cas.14003
   PubMed Web of Science ®Google Scholar
• Ioka T, Ueno M, Oh D-Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(4_suppl):387. doi:10.1200/JCO.2019.37.4_suppl.387
   Web of Science ®Google Scholar
• Yoo C, Oh DY, Choi HJ, et al. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: preliminary results from a phase I trial. Ann Oncol. 2018;29:viii258–viii9. doi:10.1093/annonc/mdy282.140
   Web of Science ®Google Scholar
• Koido S, Kan S, Yoshida K, et al. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer Res. 2014;34(11):6353–6361.
   PubMed Web of Science ®Google Scholar
• Liu WM, Fowler DW, Smith P, et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115–123. doi:10.1038/sj.bjc.6605465
   PubMed Web of Science ®Google Scholar
• Chen X, Wu X, Wu H, et al. SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study. J Clin Oncol. 2019;37(15_suppl):4092. doi:10.1200/JCO.2019.37.15_suppl.4092
   Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, Phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621. doi:10.1016/S2468-1253(19)30086-X
   PubMed Web of Science ®Google Scholar
• Oh D-Y, Lee K-H, Lee D-W, et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). J Clin Oncol. 2020;38(15_suppl):4520. doi:10.1200/JCO.2020.38.15_suppl.4520
   Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma[J]. J Hepatol. 2017;67(3):632. doi:10.1016/j.jhep.2017.03.026
   PubMed Web of Science ®Google Scholar
• Lin J, Shi W, Zhao S, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing. J Clin Oncol. 2018;36(4_suppl):500. doi:10.1200/JCO.2018.36.4_suppl.500
   Web of Science ®Google Scholar
• Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23(12):1407–e136. doi:10.1634/theoncologist.2018-0044
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Shroff RT. New treatment options for advanced biliary tract cancer. Curr Treat Options Oncol. 2020;21(8). doi:10.1007/s11864-020-00767-3
   PubMed Web of Science ®Google Scholar
• Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership. Crit Rev Oncol Hematol. 2017;111:124–132. doi:10.1016/j.critrevonc.2017.01.017
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. doi:10.1016/S1470-2045(17)30380-7
   PubMed Web of Science ®Google Scholar
• Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer. 2019;7(1):204. doi:10.1186/s40425-019-0692-z
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Liu J, et al. Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report. Onco Targets Ther. 2019;12:5389–5393. doi:10.2147/OTT.S208926
   PubMed Web of Science ®Google Scholar
• Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123(7):2756–2763. doi:10.1172/JCI69219
   PubMed Web of Science ®Google Scholar
• Park YJ, Kuen DS, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018;50(8):109. doi:10.1038/s12276-018-0130-1
   PubMedGoogle Scholar
• Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer. 2019;7(1):125. doi:10.1186/s40425-019-0596-y
   PubMedGoogle Scholar
• Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099–1109. doi:10.21037/jgo.2019.08.08
   PubMed Web of Science ®Google Scholar
• Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76(13):3767–3772. doi:10.1158/0008-5472.CAN-16-0170
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systemic review-based approach. Ann Oncol. 2019;30(8):1232–1243. doi:10.1093/annonc/mdz116
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–662. doi:10.21037/jgo.2018.08.18
   PubMed Web of Science ®Google Scholar
• Salem ME, Puccini A, Grothey A, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018;16(5):805–812. doi:10.1158/1541-7786.MCR-17-0735
   PubMed Web of Science ®Google Scholar
• Chen X, Wu H, Wu X, et al. Biomarker exploration for SHR-1210 plus GEMOX as first-line treatment in advanced biliary tract cancer. J Clin Oncol. 2020;38(4_suppl):536. doi:10.1200/JCO.2020.38.4_suppl.536
   Web of Science ®Google Scholar
• Jing CY, Fu YP, Yi Y, et al. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019;7(1):77. doi:10.1186/s40425-019-0554-8
   PubMed Web of Science ®Google Scholar
• Uemura T, Hida T. Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. J Thorac Dis. 2018;10(Suppl S9):S1108–s12. doi:10.21037/jtd.2018.03.180
   PubMedGoogle Scholar
• Mima K, Nakagawa S, Sawayama H, et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett. 2017;402:9–15. doi:10.1016/j.canlet.2017.05.001
   PubMed Web of Science ®Google Scholar
• Zhao L, Yang Y, Ma B, et al. Factors influencing the efficacy of anti-PD-1 therapy in Chinese Patients with advanced melanoma. J Oncol. 2019;2019:6454989. doi:10.1155/2019/6454989
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systemic review and meta-analysis. J Natl Cancer Inst. 2019;111(8):772–781. doi:10.1093/jnci/djz094
   PubMedGoogle Scholar
• Wallis CJD, Butaney M, Satkunasivam R, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systemic review and meta-analysis. JAMA Oncol. 2019;5(4):529–536. doi:10.1001/jamaoncol.2018.5904
   PubMed Web of Science ®Google Scholar
• Hassler MR, Abufaraj M, Kimura S, et al. Impact of patients’ gender on efficacy of immunotherapy in patients with metastatic kidney cancer: a systemic review and meta-analysis. Clin Genitourin Cancer. 2019.
   Google Scholar
• Jain V, Hwang WT, Venigalla S, et al. Association of age with efficacy of immunotherapy in metastatic melanoma. Oncologist. 2019.
   Web of Science ®Google Scholar
• José J, Marin G, Prete MG, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020.
   Web of Science ®Google Scholar